Gilead Sciences | GILD - Selling And Administration Expenses


Gilead Sciences reported $1.52B in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
ALKERMES USD 190.54M 6.1M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amgen USD 1.68B 40M Sep/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.12B 305M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Glaxosmithkline GBP 2.38B 264M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
J&J USD 6.25B 168M Sep/2026
Merck USD 2.86B 25M Sep/2026
Moderna USD 282M 66M Sep/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.31B 325M Sep/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026